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Influence of Weight Reduction on Blood Pressure
A Meta-Analysis of Randomized Controlled Trials
Judith E. Neter, Bianca E. Stam, Frans J. Kok, Diederick E. Grobbee, Johanna M. Geleijnse
Abstract—Increased body weight is a strong risk factor for hypertension. A meta-analysis of randomized controlled trials
was performed to estimate the effect of weight reduction on blood pressure overall and in population subgroups.
Twenty-five randomized, controlled trials (comprising 34 strata) published between 1966 and 2002 with a total of 4874
participants were included. A random-effects model was used to account for heterogeneity among trials. A net weight
reduction of5.1 kg (95% confidence interval [CI],6.03 to4.25) by means of energy restriction, increased physical
activity, or both reduced systolic blood pressure by 4.44 mm Hg (95% CI, 5.93 to 2.95) and diastolic blood
pressure by 3.57 mm Hg (95% CI, 4.88 to 2.25). Blood pressure reductions were 1.05 mm Hg (95% CI, 1.43
to 0.66) systolic and 0.92 mm Hg (95% CI, 1.28 to 0.55) diastolic when expressed per kilogram of weight loss.
As expected, significantly larger blood pressure reductions were observed in populations with an average weight loss
5 kg than in populations with less weight loss, both for systolic (6.63 mm Hg [95% CI, 8.43 to 4.82] vs
2.70 mm Hg [95% CI, 4.59 to 0.81]) and diastolic (5.12 mm Hg [95% CI, 6.48 to 3.75] vs 2.01 mm Hg
[95% CI,3.47 to0.54]) blood pressure. The effect on diastolic blood pressure was significantly larger in populations
taking antihypertensive drugs than in untreated populations (5.31 mm Hg [95% CI,6.64 to3.99] vs2.91 mm Hg
[95% CI, 3.66 to 2.16]). This meta-analysis clearly shows that weight loss is important for the prevention and
treatment of hypertension. (Hypertension. 2003;42:878-884.)
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Hypertension is an established risk factor for cardiovas-cular diseases and is common among obese subjects.1 In
Western societies, the prevalence of obesity is increasing,
which is likely to increase the burden of hypertension and
consequently, of cardiovascular mortality.2 From 1960 to
2000, the prevalence of obesity (body mass index [BMI] 30
kg/m2) for American adults aged 20 to 74 years increased
from 13.4% to 30.9%. In 2000, the prevalence of overweight
(BMI 25 kg/m2) for American adults was 64.5%.3 Weight
loss has been proposed as an effective, nonpharmacologic
means for the primary prevention of hypertension.4 An early
meta-analysis by Staessen et al5 in 1988 showed a reduction
in systolic blood pressure (SBP) and diastolic blood pressure
(DBP) of 2.4 and 1.5 mm Hg per kilogram weight loss,
respectively.
Targeted weight loss interventions in population subgroups
might be more effective for the prevention of hypertension
than a general-population approach because of interindividual
differences in BP and body weight. In the present meta-anal-
ysis of 25 randomized controlled trials (RCTs), both the
overall and subgroup effects of body weight reduction on BP
were assessed. This stratified meta-analysis could strengthen
the scientific basis for weight control as an important ingre-
dient of hypertension control programs in the community and
in individual patients.
Methods
Selection of Studies
Systematic literature searches in electronic databases (Cab Abstract,
Current Contents, FSTA, and MEDLINE Advanced) were conducted
for RCTs of weight reduction and BP by using the search phrase
(overweight OR weight reduction OR obes* OR weight OR diet*)
AND (hypertension OR blood pressure) AND (trial OR intervention
OR random* OR study) as title words or MeSH terms. Article
reference lists were examined for additional articles.
Trials that fulfilled the following criteria were eligible for meta-
analysis: (1) an RCT design, (2) published after 1966, (3) conducted
in humans, (4) written in English, and (5) nonpharmacologic
reduction of body weight. A total of 97 articles was identified, of
which 72 were excluded on the basis of the predefined criteria
(literature list of excluded trials is available from the authors); ie,
they did not fulfill the inclusion criteria (n21), the intervention
period was8 weeks (n2), there were co-interventions from which
the effect of weight loss could not be separated (n28), inappropri-
ate or missing BP data (n5), study objective was not weight
reduction (n4), or overlapping data with other publication(s)
(n12). Figure 1 shows the number of studies that were identified
and excluded at different stages of the selection process. A total of 25
trials6–30 proved eligible for this meta-analysis.
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Data Abstraction
Original articles were retrieved for data abstraction. Two investiga-
tors (J.E.N., B.E.S.) independently collected data on population
characteristics, study design, and treatment effect on a standard form.
For trials in which BP and body weight measurements were recorded
at several points in time,6–14 data were abstracted for the intervention
period during which the maximal BP effect was achieved. If
intermediate measurements were not reported, then the total inter-
vention period was used.15–30 Different types of weight intervention
could have been examined within the same trial, ie, energy restric-
tion, increased physical activity, or the combined intervention. When
this was the case, these interventions were analyzed as separate
strata. For 2 trials, the authors were contacted to obtain missing
data.15,25 For 1 trial, in which the age of the trial population was not
reported, the mean age of other trial populations combined (ie, 46
years) was imputed in the data analysis.28
Quantitative Data Synthesis
Changes in BP from baseline in the control group were subtracted
from changes in the intervention group to obtain the net BP effect of
weight reduction. SEs of the treatment effect were also abstracted. If
not reported, SEs were derived from SDs or SEs for BP effects
within groups, confidence intervals (CIs), test statistics, or probabil-
ity values. For estimations of SE, a correlation of 0.5 between the
variances at baseline and at follow-up within each group was
assumed, according to Follmann et al,31 as follows:
SE{(SEbaseline)2(SEfollow-up)2(20.5SEbaselineSEfollow-up)}
In one article,26 variance measures were not presented, so SE was
predicted from all other trials by means of linear regression by using
the trial sample size as the independent variable.
A random-effects model was chosen for meta-analysis to account
for heterogeneity in BP effect among trials. An advanced statistical
technique for meta-analysis of continuous outcomes was applied that
takes into account both within- and between-study variation (SAS
PROC MIXED).32 The weight factor by which BP effects were
weighted was 1/(SE22), where  is the between-study variation.
To examine the effect modification of BP response to weight loss,
meta-analyses were performed in predefined strata of mean age (45
vs 45 years), gender (50% vs 50% females), type of interven-
tion (energy restriction vs increased physical activity vs combined
intervention), race (white vs black vs Asian), initial BMI (30 vs
30 kg/m2), antihypertensive treatment (no vs yes; coded as “yes” if
1 or more subjects were being treated with antihypertensive drugs),
weight loss (5 vs 5 kg), and baseline hypertensive status (yes vs
no; based on initial BP level only, ie,140/90 vs 140/90 mm Hg).
Stratified meta-analyses were repeated with a multivariate model to
adjust for potential confounders, ie, mean age, gender (percent
females), initial BP, change in body weight of trial populations, and
duration of intervention.
A funnel plot of SBP effect against the weight factor was visually
examined for potential publication bias (Figure 2). The funnel plot
was roughly symmetrical about the mean-effect size line, except for
the outlying study by Reisin et al.27 For this reason, meta-analyses
were also performed after exclusion of this study.
Results
Overview of Trials
The population and study characteristics of trials of weight
reduction and BP are presented in Table 1. The analysis was
based on 25 parallel trials published between 1978 and 2002,
comprising 34 strata with a total of 4874 subjects. The
duration of intervention until the maximal BP effect (or, if not
reported the overall BP effect) was achieved varied between
8 and 260 weeks. Most studies (82%) included both men and
women. The mean age of trial populations ranged from 37 to
66 years. Half of the populations were hypertensive (on the
basis of initial BP cutoff level of 140/90 mm Hg), and 24% of
the populations were taking antihypertensive medication.
Mean total duration was 66.6 weeks, and mean duration until
the maximal BP effect was achieved was 35.3 weeks. The
overall percentage of subjects in RCTs who dropped out after
randomization was small (4.8%).
Figure 1. Selection of RCTs for meta-analysis of weight reduc-
tion and BP.
Figure 2. Funnel plot to explore publication bias in 25 RCTs of
weight reduction and BP. Open squares represent individual
trials (or trial strata); net change in SBP is plotted against the
reciprocal of its variance (weight factor). The funnel plot was
roughly symmetrical about the mean-effect size (vertical line),
except for the outlying study by Reisin et al.27
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Changes in Body Weight
Mean initial body weight and BMI were 88.3 kg and 30.7
kg/m2, respectively. Mean net change in body weight of the
population was 5.8% of initial body weight, ie, 5.1 kg
(95% CI, 6.03 to 4.25), ranging from 0.6 to 11.9
kg. Average weight reductions in the energy restriction,
increased physical activity, and combined intervention
subgroups were 6.7 kg (95% CI, 8.27 to 5.11), 3.1
kg (95% CI, 4.54 to 1.75), and 6.2 kg (95% CI,
7.87 to 4.55), respectively.
Changes in BP
Forest plots for net changes in SBP and DBP due to weight
reduction, with 95% CIs, are presented in Figure 3. An
average net weight reduction of 5.1 kg by means of energy
restriction, increased physical activity, or the combined in-
tervention was associated with a significant reduction in SBP
of4.44 mm Hg (95% CI,5.93 to2.95) and a significant
reduction in DBP of 3.57 mm Hg (95% CI, 4.88 to
2.25). When expressed per kilogram of weight loss, reduc-
tions in SBP and DBP were 1.05 mm Hg (95% CI, 1.43
TABLE 1. Population and Study Characteristics of RCTs of Weight Reduction and BP
Study* Year N†
Duration,
wk‡
Age,
y
Females,
% Race
Drug
Treated§ Intervention
BMI,
kg/m2
Body Weight, kg SBP, mm Hg DBP, mm Hg
Initial Change Initial
Change
(SE) Initial
Change
(SE)
Anderssen et al15a 1995 95 52 45 10 W No EN 29.0 91.5 5.1 131.0 5.9 (2.20) 87.3 2.7 (1.64)
Anderssen et al15b 1995 92 52 45 10 W No PA 28.5 89.5 2.0 130.5 1.6 (2.02) 88.2 2.0 (1.64)
Anderssen et al15c 1995 108 52 45 10 W No EN, PA 28.5 89.8 6.7 130.6 5.4 (2.02) 87.6 4.5 (1.58)
Andersson et al16 1991 18 17 53 100 W No EN 29.4 80.9 6.0 144.5 7.0 (6.08) 93.0 8.0 (4.48)
Anonymous6 1990 233 156 (26) 39 33 W, B No EN 28.5 85.4 5.8 125.0 5.1 (1.00) 83.2 2.8 (1.00)
Anonymous7 1997 1099 208 (26) 43 34 W, B No EN, PA 31.0 93.5 4.5 127.4 3.8 (0.49) 85.9 2.7 (0.39)
Ard et al17 2000 44 8 40 96 B Yes EN, PA 37.8 101.4 6.7 123.6 4.3 (1.31) 79.3 2.5 (1.13)
Blumenthal et al18a 2000 68 26 48 57 W, B No EN, PA 32.3 93.5 8.6 143.0 8.3 (5.86) 93.6 7.0 (3.15)
Blumenthal et al18b 2000 66 26 47 51 W, B No PA 32.7 95.0 2.5 139.9 5.3 (5.87) 93.8 5.7 (3.00)
Blumenthal et al18c 2000 90 26 48 58 W, B No EN 32.4 94.3 6.1 140.4 3.0 (4.93) 93.4 1.3 (2.74)
Croft et al8 1986 130 52 (26) 48 48 . . .¶ No EN ...# 84.5 6.3 161.0 7.0 (2.58) 97.0 6.0 (1.47)
Fagerberg et al9 1984 30 20 (12) 51 0 W No EN 30.8 97.5 8.6 152.6 6.2 (5.57) 101.0 0.5 (2.89)
Fortmann et al19a 1988 73 52 44 0 . . .¶ No EN 29.5 93.4 7.4 119.0 1.6 (1.90) 79.5 3.0 (1.90)
Fortmann et al19b 1988 77 52 44 0 . . .¶ No PA 29.2 94.5 5.1 121.1 2.5 (1.90) 78.5 1.5 (1.90)
Gordon et al20 1997 33 12 49 69 . . .¶ No EN 33.8 96.6 6.1 145.0 2.6 (2.24) 95.4 2.0 (1.58)
Haynes et al21 1984 51 26 47 33 . . .¶ No EN . . .# 91.9 3.3 134.5 5.0 (3.94) 90.1 1.5 (1.11)
He et al10 2000 95 364 (78) 43 47 W, B No EN, PA 28.9 85.1 3.5 122.3 5.8 (1.47) 84.3 3.2 (1.12)
Jalkanen et al22 1991 49 52 49 50 W Yes EN 30.5 82.9 4.0 153.5 7.0 (4.68) 101.5 0.0 (2.34)
Lalonde et al23a 2002 19 12 46 74 . . .¶ Yes PA 28.8 79.0 3.7 134.3 3.1 (5.80) 84.6 0.0 (3.76)
Lalonde et al23b 2002 22 12 46 55 . . .¶ Yes PA 28.4 77.7 1.2 130.6 0.7 (4.00) 83.3 0.4 (3.05)
Langford et al24 1991 180 26 48 51 W, B No EN . . .# 87.7 3.7 143.9 1.2 (1.19) 93.9 0.8 (1.47)
MacMahon et al11 1985 38 25 (21) 41 24 . . .¶ No EN 32.9 95.9 7.9 150.0 5.9 (1.64) 100.1 6.7 (1.86)
Masuo et al25a 2002 40 24 37 0 A No PA 27.5 82.7 4.1 154.0 1.0 (2.64) 101.5 4.0 (2.45)
Masuo et al25b 2002 40 24 37 0 A No EN 27.6 83.3 1.4 152.0 6.0 (2.64) 100.0 5.0 (2.64)
Oberman et al26 1990 163 26 49 45 W, B No EN 30.4 88.0 3.5 143.4 1.4 (2.75) 93.3 1.3 (1.95)
Reisin et al27 1978 83 26 47 37 . . .¶ Yes EN . . .# 83.5 9.1 171.4 30.5 (6.01) 111.6 20.8 (2.50)
Singh et al28 1990 206 13 46 21 A Yes EN . . .# 66.7 11.9 154.2 16.3 (1.46) 99.5 12.0 (0.86)
Singh et al29 1995 217 16 47 22 A Yes EN 24.6 66.7 2.8 153.7 7.5 (2.01) 100.1 6.5 (1.59)
Stamler et al30 1989 194 260 38 13 W, B No EN . . .# 84.3 2.7 122.2 2.0 (0.90) 82.2 1.9 (0.80)
Stevens et al12 1993 538 78 (26) 43 32 W, B No EN, PA 29.5 89.8 5.6 124.4 3.8 (0.70) 83.8 2.5 (0.60)
Whelton et al13 1998 488 156 (13) 66 48 W, B Yes EN, PA 28.9 81.1 1.9 128.0 3.2 (1.53) 71.3 0.3 (0.94)
Wing et al14a 1998 67 104 (26) 45 79 . . .¶ No EN 36.0 98.5 7.6 115.3 8.2 (1.83) 73.5 4.0 (2.42)
Wing et al14b 1998 65 104 (26) 46 80 . . .¶ No PA 36.0 98.3 0.6 115.2 0.4 (2.55) 73.8 0.5 (3.78)
Wing et al14c 1998 63 104 (26) 46 79 . . .¶ No EN, PA 35.9 98.1 8.8 117.0 10.3 (2.34) 74.4 4.7 (2.52)
W indicates white; B, black; A, Asian; EN, energy restriction; and PA, increased physical activity.
*a, b, and c suffixes denote different strata from the same study.
†No. of subjects who completed the trial.
‡Total follow-up period is in weeks; duration until maximal BP effect is given in parentheses for trials for which these data were available.6–14
§Coded yes if trial population included 1 or more subjects on antihypertensive drug treatment.
Maximal change or, if not available, change for total follow-up period.
¶Either the population belonged to a race category other than black, white, or Asian or information on race was not provided in the article.
#Initial BMI of the study population could not be derived from the article.
880 Hypertension November 2003
to 0.66) and 0.92 mm Hg (95% CI, 1.28 to 0.55),
respectively. Exclusion of the outlying study by Reisin et al27
caused a small attenuation of the overall estimates, ie,
4.17 mm Hg (95% CI, 5.55 to 2.80) for SBP and
3.12 mm Hg (95% CI, 4.17 to 2.07) for DBP.
BP Response in Subgroups
Findings from stratified meta-analyses are presented in Table
2. In the stratified meta-analysis, larger BP reductions were
observed in populations with an average weight loss 5 kg
than in populations with less weight loss, both for SBP
(6.24 mm Hg [95% CI, 8.06 to 4.41] vs 2.44 mm Hg
[95% CI, 4.38 to 0.49]) and DBP (4.97 mm Hg [95%
CI, 6.62 to 3.31] vs 1.97 mm Hg [95% CI, 3.71 to
0.21]). BP reductions were also larger in populations who
were taking antihypertensive medication than in untreated
populations, both for SBP (7.00 mm Hg [95% CI, 10.02
to 3.98] vs 3.77 mm Hg [95% CI, 5.33 to 2.22]) and
DBP (5.49 mm Hg [95% CI, 8.06 to 2.93] vs
2.97 mm Hg [95% CI, 4.39 to 1.55]). When subgroups
were compared on the basis of initial BP level (140/
90 mm Hg vs 140/90 mm Hg), there was no difference in
SBP response, but reductions in DBP were approximately
twice as large in hypertensives, although this difference was
not statistically significant (4.92 [95% CI,6.73 to3.12]
vs 2.35 [95% CI, 4.05 to 0.65]). Weight loss caused
larger BP reductions in Asian than in white or black popula-
tions, both for SBP and DBP, but findings must be interpreted
with caution because of limited statistical power. Age, initial
BMI, gender (percent females), and type of intervention did
not significantly influence SBP and DBP response to weight
loss in unadjusted analyses (Table 2).
Excluding the study of Reisin et al27 yielded a smaller
contrast in BP response between treated and untreated pop-
ulations, ie, 5.87 mm Hg (95% CI, 8.79 to 2.94) versus
3.79 mm Hg [95% CI, 5.25 to 2.32] for SBP and
3.90 mm Hg (95% CI, 6.10 to 1.70) versus
2.90 mm Hg (95% CI, 4.06 to 1.74) for DBP.
Findings from multivariate stratified analyses were consis-
tent with univariate results (Table 2), except for strongly
increased BP estimates for intervention with physical activity
(4.74 mm Hg [95% CI, 7.60 to 1.88] for SBP and
4.65 mm Hg [95% CI, 6.84 to 2.45] for DBP), which
resulted from correction for the amount of weight reduction.
Discussion
This meta-analysis of 25 RCTs comprising 4874 participants
from different ethnic populations showed a BP reduction of
4.4/3.6 mm Hg for an 5-kg weight loss by means of
energy restriction, physical activity, or both. Larger BP
reductions were achieved in populations that included sub-
jects taking antihypertensive drugs.
Our meta-analysis was based on trials with an RCT design,
which have high internal validity. For trials in which BP
measurements were repeatedly recorded during follow-up,
data were abstracted at the time point when the maximal
effect of weight reduction on BP was achieved (32% of the
strata). In most of these RCTs, the maximal effect was
reached before the end of the trial. A likely explanation is
lack of compliance during long-term intervention.
A previous meta-analysis of 12 trials by Staessen et al,5
published in 1988, showed a BP reduction of 2.4/
1.5 mm Hg per kilogram weight loss, which is substantially
larger than our estimate (1.1/0.9 mm Hg per kg). How-
ever, half of the studies in the meta-analysis by Staessen et al5
were not randomized, and only 2 trials overlapped with our
study, which might explain this discrepancy. The results of
our subgroup analysis by hypertensive status are not consis-
Figure 3. BP effects in RCTs of weight reduction and BP. Open
squares represent average net changes in SBP (Forest plot A)
and DBP (Forest plot B) in individual trials (or trial strata), with
95% CIs; pooled estimates from meta-analysis are depicted as
gray diamonds; a, b, and c suffixes denote different strata from
the same trial.
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tent with the meta-analysis of 8 RCTs by Ebrahim and
Smith,33 in which the BP response was larger in hypertensive
populations (5.2/5.2 mm Hg) than in normotensive pop-
ulations (2.8/2.3 mm Hg). However, hypertension in our
analysis was defined on the basis of BP level only and not on
use of antihypertensive medication, which accounts for part
of this difference. The Cochrane review by Mulrow et al34
showed that modest weight loss in the range of 3% to 9% of
initial body weight was roughly associated with a 3-mm Hg
reduction in BP in overweight, hypertensive persons, which is
smaller than in our study. Mulrow et al34 did not perform
pooling of trials because of marked heterogeneity in study
designs, entry criteria, and outcome measurement. Most of
the 18 trials in their meta-analysis included combined inter-
ventions (eg, weight reduction plus sodium restriction), from
which the effect of body weight reduction could not be
separated.
A meta-analysis of aerobic exercise and BP by Whelton et
al35 showed that BP was significantly reduced even in trials in
which overall weight loss was minimal. This suggests that
exercise reduces BP independently of changes in body
weight. In our multivariate analysis, which was standardized
for the amount of weight loss, the effect on DBP was larger
when body weight was reduced by physical activity com-
pared with energy restriction. This confirms the idea that
physical activity also reduces BP by mechanisms unrelated to
weight loss.
Although the exact mechanism of the relation between
hypertension and obesity and the effect of weight loss on BP
is unknown, there are several plausible biologic pathways.1
The renin-angiotensin-aldosterone system is overactivated in
obese subjects, and renin activity and aldosterone concentra-
tions are higher than in lean subjects.36–38 Furthermore,
activity of the sympathetic nervous system is increased in
TABLE 2. Changes in SBP and DBP in 25 RCTs of Weight Reduction and BP, Overall and in Subgroups
Stratum No. of Strata*
SBP, mm Hg† DBP, mm Hg†
Unadjusted Adjusted‡ Unadjusted Adjusted‡
Overall 34 4.44 (5.93; 2.95) 4.78 (5.76; 3.80) 3.57 (4.88; 2.25) 3.56 (4.31; 2.81)
Age
45 years 15 4.19 (6.19; 2.20) 4.74 (6.35; 3.12) 3.17 (5.04; 1.31) 3.69 (4.96; 2.43)
45 years 19 4.74 (6.95; 2.52) 4.80 (6.48; 3.13) 3.94 (5.76; 2.12) 3.43 (4.63; 2.23)
Gender
50% females 21 4.75 (6.54; 2.97) 5.05 (6.10; 3.99) 4.04 (5.61; 2.48) 3.89 (4.66; 3.12)
50% females 13 3.74 (6.40; 1.07) 3.91 (5.69; 2.13) 2.53 (4.82; 0.24) 2.50 (3.93; 1.08)
Hypertension§
No 17 4.08 (6.01; 2.16) 4.46 (5.71; 3.21) 2.35 (4.05; 0.65) 2.62 (3.83; 1.42)
Yes 17 4.95 (7.25; 2.64) 4.73 (6.40; 3.06) 4.92 (6.73; 3.12) 4.36 (5.72; 3.00)
Race
White 14 3.19 (4.79; 1.59)    2.50 (3.00; 1.99)   
Black 4 4.67 (8.86; 0.49)    3.08 (4.92; 1.23)   
Asian 4 8.77 (11.91; 5.64)    9.81 (11.17; 8.44)   
Intervention
Energy restriction 19 4.93 ( 6.84; 3.02) 4.33 (5.70; 2.97) 4.25 (5.95; 2.55) 2.84 (3.80; 1.87)
Physical activity 8 1.73 (5.14; 1.69) 4.74 (7.60; 1.88) 1.93 (5.07; 1.22) 4.65 (6.84; 2.45)
Combined intervention 7 5.15 (7.78; 2.51) 5.66 (7.52; 3.81) 3.12 (5.60; 0.64) 4.44 (5.68; 3.19)
Initial BMI
30 kg/m2 15 4.14 (4.95; 3.33) 4.59 (5.70; 3.49) 2.61 (3.29; 1.93) 3.11 (4.01; 2.21)
30 kg/m2 13 4.09 (4.87; 3.31) 4.05 (5.06; 3.05) 2.75 (3.39; 2.11) 2.77 (3.50; 2.04)
Weight reduction
5 kg 16 2.44 (4.38; 0.49) 2.70 (4.59; 0.81) 1.97 (3.71; 0.21) 2.01 (3.47; 0.54)
5 kg 18 6.24 (8.06; 4.41) 6.63 (8.43; 4.82) 4.97 (6.62; 3.31) 5.12 (6.48; 3.75)
Antihypertensive drugs¶
No 26 3.77 (5.33; 2.22) 4.11 (5.23; 3.00) 2.97 (4.39; 1.55) 2.91 (3.66; 2.16)
Yes 8 7.00 (10.02; 3.98) 6.70 (8.71; 4.69) 5.49 (8.06; 2.93) 5.31 (6.64; 3.99)
*No. of strata in subgroup analyses may not total 34 because of missing data.
†BP changes were obtained from a random-effects model, with 95% CI end points in parentheses.
‡Adjusted for age, gender (% females), initial BP, change in body weight, and duration.
§Based on initial BP level (140/90 mm Hg vs 140 mm Hg), not on use of antihypertensive medication.
Races other than black, white, and Asian were not considered in subgroup analysis because of small numbers; power for multivariate analysis in strata of race
was insufficient.
¶Coded “yes” if trial population included one or more subjects on antihypertensive drug treatment.
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hypertensive, obese subjects, which could induce obesity-
related renal effects.38–40 Alternatively, there might be inhi-
bition of the natriuretic peptides system, of which the func-
tional effects are vasodilatation and natriuresis.38,41,42
Decreased insulin sensitivity and hyperinsulinemia as part of
the metabolic syndrome might also form an essential link
between obesity and hypertension, although this interrelation
is still not fully understood.43
Additional studies are needed to investigate the long-term
effects of weight reduction on BP. It is also important to
examine whether weight loss has a persistent beneficial effect
on cardiovascular risk, even after regaining weight. Data on
weight reduction and BP in children and adolescents are
scanty. Trials in this field are clearly warranted because of the
increasing prevalence of obesity and hypertension at younger
ages, which is becoming a major medical problem and a
threat to public health.44
In conclusion, the results from this meta-analysis provide
unequivocal evidence that weight loss makes an important
contribution to the treatment of hypertension, especially in
subjects taking antihypertensive medication. Prevention of
weight gain is likely to have a large impact on the burden of
hypertension and consequently, cardiovascular diseases in the
general population.
Perspectives
This meta-analysis of 25 RCTs showed reductions in SBP
and DBP of 1 mm Hg for each kilogram of weight loss. In
particular, subjects on antihypertensive drug treatment might
benefit from weight reduction. This study provides unequiv-
ocal evidence that lifestyle modifications to reduce body
weight should be a major component in the treatment of
hypertension. The prevalence of overweight in Western
societies has strongly increased in the past decades. Weight
control in the population is of the utmost importance to
prevent an increase in the prevalence of hypertension and
consequently, of cardiovascular morbidity and mortality.
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